Investor FAQ

Show all

The Company is headquartered in Seattle, Washington. Click here for Company contact information.
The Company is incorporated in the state of Delaware.
The Company’s spin-off from Emergent BioSolutions occurred on August 1, 2016 and involved a distribution of 100 percent of the Company’s common to Emergent BioSolutions stockholders of record as of July 22, 2016, or the distribution. The share distribution ratio was 1 share of the Company for every 2 shares of Emergent BioSolutions.
Except for any cash received in lieu of a fractional ordinary share, we anticipate that a U.S. stockholder generally will not recognize any income, gain or loss as a result of the receipt of the Company’s common shares in the distribution. For more information about the tax consequences of the spin-off, see “Material U.S. Federal Income Tax Consequences” in our information statement, attached as exhibit 99.1 to Company’s Current Report on Form 8-K, filed on August 1, 2016.

YOU ARE URGED TO CONSULT YOUR TAX ADVISOR WITH RESPECT TO THE SPECIFIC TAX CONSEQUENCES TO YOU OF THE DISTRIBUTION, INCLUDING THE EFFECTS OF U.S. FEDERAL, STATE, LOCAL AND FOREIGN TAX RULES AND THE EFFECT OF POSSIBLE CHANGES IN LAWS THAT MAY AFFECT THE TAX CONSEQUENCES DESCRIBED ABOVE.
The Company’s common stock is traded on the NASDAQ Global Select Market under the ticker symbol “APVO”. Click here to view a stock quote.
The CUSIP number for the Company’s common stock is 03835L 10 8.
The Company operates on a calendar quarterly basis, with its year ended December 31.
The Company’s transfer agent and registrar is Broadridge Financial Solutions, Inc. They can be contacted at the following:

Broadridge Corporate Issuer Solutions, Inc.
P.O. Box 1342
Brentwood, NY 11717
(toll free) 877/830-4936
(international) 720/378-5591
(email) shareholder@broadridge.com
(website) www.broadridge.com/BCIS
Contact the Company’s transfer agent and registrar as follows:

Broadridge Corporate Issuer Solutions, Inc.
P.O. Box 1342
Brentwood, NY 11717
(toll free) 877/830-4936
(international) 720/378-5591
(email) shareholder@broadridge.com
(website) www.broadridge.com/BCIS
Contact the Company’s transfer agent and registrar as follows:

Broadridge Corporate Issuer Solutions, Inc.
P.O. Box 1342
Brentwood, NY 11717
(toll free) 877/830-4936
(international) 720/378-5591
(email) shareholder@broadridge.com
(website) www.broadridge.com/BCIS
No, the Company’s stock can only be purchased through a stockbroker or registered investment advisor.
The Company is audited by Ernst & Young LLP.
The Company currently intends to retain any and all of its future earnings to finance the growth and development of its business. The Company does not intend to pay cash dividends to its stockholders in the foreseeable future.
The Company’s news releases can be viewed under Press Releases.
The Company’s filings with the Securities and Exchange Commission can be viewed under SEC Filings.
Click here for the Company’s Management Team or Board of Directors.
For copies of the Company’s Investor information, please click here. For an online version of the Company’s Investor kit, please click here.
All investor inquiries are to be directed to the following:

Jeff Lamothe
Senior Vice President, Chief Financial Officer
Aptevo Therapeutics Inc.
Direct: 206/838-0500
Email: jlamothe@apvo.com